A Phase 1/2 interventional study of Smoflipid in Sepsis, Severe and Septic Shock, sponsored by University of Florida. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-11.
Sponsored by University of Florida · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Shock, Septic with a site in United States — 19 open to participants now, 26 under way, 1 of them phase 3. Shock, Septic · United States.
Among the 164 studies in Shock, Septic with a site in United States, this one is the 52nd largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2018, is one of 7 in phase 1/2, and was the 96th registered.
1,080 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.
Browse Shock, Septic studies →19 of the 164 studies in Shock, Septic with a site in United States are open now. Recruiting first, the newest first:
Intermountain Health Care, Inc. · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
University of Pennsylvania · Sites in United States
Ages 18–80
The Cleveland Clinic · Sites in United States
Ages 18+
Brett A Faine · Sites in United States
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 137 Shock, Septic studies recruiting now, 102 (74%) set no upper age limit and 19 (14%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 38 · Phase 3 17 · Phase 4 15
First in 1992; this study’s year is marked. 13 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 80 across 636 interventional studies indexed under Shock, Septic.
Median enrollment 50 across the 116 interventional studies, 330 across the 47 observational. Of the 110 that completed or were terminated, 47 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 164 have an industry lead sponsor. The 10 most frequent:
University of Florida is the lead sponsor of 1,289 studies on the registry; 201 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
University of Florida has 4 studies filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
11 of the studies in Shock, Septic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01315782The University of Texas Health Science Center, HoustonAlveolar Dead Space as Predictor of Organ Failure in Severe Sepsis | 2026-12 |
| NCT07425587Bluejay Diagnostics, Inc.Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study | 2026-12-30 |
| NCT06654895Bluejay Diagnostics, Inc.Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study | 2026-12-31 |
| NCT05011656ExThera Medical CorporationBlood Purification for the Treatment of Pathogen Associated Shock | 2026-12-31 |
| NCT06693726Brett A FaineEarly Angiotensin II in the Emergency Department | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 164 studies in Shock, Septic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Briefly, this pilot clinical trial will evaluate preliminary safety and efficacy of the study drug (Smoflipid) at elevating cholesterol levels (primary outcome) in patients with sepsis and moderate organ dysfunction and will also evaluate measures of organ dysfunction, mortality, and biological activity (secondary outcomes).
Sepsis is a life-threatening disease for which there are no effective treatments. It results from metabolic and immunologic derangements that lead to organ dysfunction, shock and sometimes death. Both "good" (high density lipoprotein, HDL) and "bad" (low density lipoprotein, LDL) cholesterol should be protective against sepsis by helping to clear bacterial toxins from the blood stream and by providing a fuel for endogenous corticosteroids, part of the body's protective stress-response in shock. However, for partially unknown reasons, cholesterol levels drop to critically low levels in early sepsis, leaving the body unable to protect itself against sepsis via these mechanisms. Currently, lipid emulsions are available that are FDA approved for intravenous nutrition in critically ill patients (including sepsis) and may be capable of elevating serum cholesterol levels. This Phase II randomized pilot clinical trial, proposes to assess the following in a cohort of patients with early sepsis (first 24 hours): 1) safety and tolerability of the proposed lipid injectable emulsion (Smoflipid) and any adverse effects, 2) the drugs ability to optimally elevate cholesterol at 48 hours, and 3) preliminary measures of biological activity and clinical outcomes.
1,080 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.
This study's enrollment of 59 is below the median of 80 across 636 interventional studies indexed under Shock, Septic.
Browse Shock, Septic studies →University of Florida is the lead sponsor of 1,289 studies on the registry; 201 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infusion of drug (Smoflipid) will occur over a 10-16.5 hour period given once per day for the first two days of study enrollment.
Drug: Smoflipid
Infusion of drug (Smoflipid) will occur over a 10-16.5 hour period given once per day for the first two days of study enrollment.
Drug: Smoflipid
Infusion of drug (Smoflipid) will occur over a 10-16.5 hour period given once per day for the first two days of study enrollment.
Drug: Smoflipid
No drug, patients will be followed as active controls
Infusion of drug (Smoflipid) will occur over a 10-16.5 hour period given once per day for the first two days of study enrollment.
Drug: Smoflipid
Infusion of drug (Smoflipid) will occur over a 10-16.5 hour period given once per day for the first two days of study enrollment.
Drug: Smoflipid
Infusion of drug (Smoflipid) will occur over a 10-16.5 hour period given once per day for the first two days of study enrollment.
Drug: Smoflipid
Infusion of drug (Smoflipid) will occur over a 10-16.5 hour period given once per day for the first two days of study enrollment.
Drug: Smoflipid
Administration of lipid injectable emulsion
Also known as: Total parenteral nutrition
Phase II - Primary Outcome - Change in Total Cholesterol (48 Hours - Enrollment)
Change in total cholesterol (48 hour - enrollment value) of 0 to +5 mg/dL
Time frame: 48 hours
Phase I - Primary Outcome - Maximum Tolerated Dose/Participants Experiencing Dose Related Toxicity
Using sequential dose escalation, participants received 2 doses of 1.0 to 1.6 g/kg of lipid emulsion (Smoflipid 20% lipid emulsion) within 48 hours of enrollment to test the maximum tolerated dose of study drug. The maximum tolerated dose was defined by patients exhibiting specific dose-related toxicities from administration of escalating doses of the study drug. Of 9 patients, adverse events were only considered dose-limiting toxicities if they met the predefined study protocol criteria. None of these were classified as dose limiting or serious.
Time frame: First 48 hours
Phase II - Secondary Outcome - Organ Dysfunction
Sequential Organ Failure Assessment (SOFA) Score, this is a numerical score ranging from 0 to 24. A Higher SOFA score represents worsening organ dysfunction is correlated with higher rate of mortality. We measured the change over 48 hours.
Time frame: 48 hours
The study has a Phase II design. After evaluating for DLT, 49 enrolled (2 withdrawals) with 47 patients completing the Phase II study to either Smoflipid (intervention) or control. Only Phase II data are reported here.
| Milestone | Phase II - 1.2 g/kg Smoflipid | Phase II - 1.4 g/kg Smoflipid | Phase II - 1.6 g/kg Smoflipid | Phase II - Control | Phase I - 1.0 g/kg Smoflipid | Phase I - 1.2 g/kg Smoflipid | Phase I - 1.4 g/kg Smoflipid | Phase I - 1.6 g/kg Smoflipid |
|---|---|---|---|---|---|---|---|---|
| Started | 11 | 4 | 10 | 24 | 2 | 2 | 3 | 3 |
| Completed | 10 | 4 | 9 | 24 | 2 | 2 | 2 | 3 |
| Not completed | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
Change in total cholesterol (48 hour - enrollment value) of 0 to +5 mg/dL
| mg/dL | Phase II - 1.2 g/kg Smoflipid | Phase II - 1.4 g/kg Smoflipid | Phase II - 1.6 g/kg Smoflipid | Phase II - Control | Phase I - 1.0 g/kg Smoflipid | Phase I - 1.2 g/kg Smoflipid | Phase I - 1.4 g/kg Smoflipid | Phase I - 1.6 g/kg Smoflipid |
|---|---|---|---|---|---|---|---|---|
| Phase II - Primary Outcome - Change in Total Cholesterol (48 Hours - Enrollment) | 9 ± 17 | -10 ± 29 | 4 ± 21 | 2 ± 18 | -12 ± 23 | 16 ± 1 | -9 ± 10 | -18 ± 9 |
Using sequential dose escalation, participants received 2 doses of 1.0 to 1.6 g/kg of lipid emulsion (Smoflipid 20% lipid emulsion) within 48 hours of enrollment to test the maximum tolerated dose of study drug. The maximum tolerated dose was defined by patients exhibiting specific dose-related toxicities from administration of escalating doses of the study drug. Of 9 patients, adverse events were only considered dose-limiting toxicities if they met the predefined study protocol criteria. None of these were classified as dose limiting or serious.
| Participants | Phase II - 1.2 g/kg Smoflipid | Phase II - 1.4 g/kg Smoflipid | Phase II - 1.6 g/kg Smoflipid | Phase II - Control | Phase I - 1.0 g/kg Smoflipid | Phase I - 1.2 g/kg Smoflipid | Phase I - 1.4 g/kg Smoflipid | Phase I - 1.6 g/kg Smoflipid |
|---|---|---|---|---|---|---|---|---|
| Phase I - Primary Outcome - Maximum Tolerated Dose/Participants Experiencing Dose Related Toxicity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sequential Organ Failure Assessment (SOFA) Score, this is a numerical score ranging from 0 to 24. A Higher SOFA score represents worsening organ dysfunction is correlated with higher rate of mortality. We measured the change over 48 hours.
| score on a scale | Phase II - 1.2 g/kg Smoflipid | Phase II - 1.4 g/kg Smoflipid | Phase II - 1.6 g/kg Smoflipid | Phase II - Control | Phase I - 1.0 g/kg Smoflipid | Phase I - 1.2 g/kg Smoflipid | Phase I - 1.4 g/kg Smoflipid | Phase I - 1.6 g/kg Smoflipid |
|---|---|---|---|---|---|---|---|---|
| Phase II - Secondary Outcome - Organ Dysfunction | 1 (-2 to 1) | 0 (-5 to 0) | -2 (-3 to -2) | -2 (-4 to -1) | 4 (3 to 4) | -5 (-6 to -4) | -2 (-3 to 0) | 0 (-2 to 2) |
Collected over Adverse event data were collected from enrollment through 28 days after enrollment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase II - 1.2 g/kg Smoflipid | 1/10 (10%) | 2/10 (20%) | 6/10 (60%) |
| Phase II - 1.4 g/kg Smoflipid | 3/4 (75%) | 3/4 (75%) | 3/4 (75%) |
| Phase II - 1.6 g/kg Smoflipid | 0/9 (0%) | 1/9 (11.1%) | 7/9 (77.8%) |
| Phase II - Control | 7/24 (29.2%) | 8/24 (33.3%) | 8/24 (33.3%) |
| Phase I - 1.0 g/kg Smoflipid | 1/2 (50%) | 2/2 (100%) | 2/2 (100%) |
| Phase I - 1.2 g/kg Smoflipid | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Phase I - 1.4 g/kg Smoflipid | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Phase I - 1.6 g/kg Smoflipid | 2/3 (66.7%) | 2/3 (66.7%) | 2/3 (66.7%) |
| Event | Phase II - 1.2 g/kg Smoflipid | Phase II - 1.4 g/kg Smoflipid | Phase II - 1.6 g/kg Smoflipid | Phase II - Control | Phase I - 1.0 g/kg Smoflipid | Phase I - 1.2 g/kg Smoflipid | Phase I - 1.4 g/kg Smoflipid | Phase I - 1.6 g/kg Smoflipid |
|---|---|---|---|---|---|---|---|---|
| IntubationRespiratory, thoracic and mediastinal disorders | 0/10 | 0/4 | 0/9 | 3/24 | 2/2 | 0/2 | 0/2 | 1/3 |
| DeathGeneral disorders | 1/10 | 3/4 | 0/9 | 7/24 | 1/2 | 0/2 | 0/2 | 2/3 |
| Hospital ReadmissionGeneral disorders | 1/10 | 0/4 | 1/9 | 0/24 | 0/2 | 0/2 | 0/2 | 0/3 |
| Vasopressor SupportGeneral disorders | 0/10 | 0/4 | 0/9 | 1/24 | 0/2 | 0/2 | 0/2 | 0/3 |
| Cardiac ArrestCardiac disorders | 0/10 | 0/4 | 0/9 | 1/24 | 0/2 | 0/2 | 0/2 | 0/3 |
| Event | Phase II - 1.2 g/kg Smoflipid | Phase II - 1.4 g/kg Smoflipid | Phase II - 1.6 g/kg Smoflipid | Phase II - Control | Phase I - 1.0 g/kg Smoflipid | Phase I - 1.2 g/kg Smoflipid | Phase I - 1.4 g/kg Smoflipid | Phase I - 1.6 g/kg Smoflipid |
|---|---|---|---|---|---|---|---|---|
| HyperglycemiaGeneral disorders | 1/10 | 0/4 | 0/9 | 0/24 | 1/2 | 1/2 | 0/2 | 1/3 |
| Elevated triglyceridesGeneral disorders | 2/10 | 0/4 | 2/9 | 3/24 | 1/2 | 1/2 | 0/2 | 1/3 |
| Elevated Total BiliGeneral disorders | 0/10 | 1/4 | 0/9 | 1/24 | 1/2 | 0/2 | 0/2 | 0/3 |
| Line infiltrationGeneral disorders | 0/10 | 0/4 | 2/9 | 0/24 | 0/2 | 0/2 | 1/2 | 1/3 |
| Elevated ALTGeneral disorders | 1/10 | 0/4 | 1/9 | 1/24 | 0/2 | 0/2 | 1/2 | 0/3 |
| Elevated ASTHepatobiliary disorders | 1/10 | 0/4 | 0/9 | 1/24 | 1/2 | 0/2 | 1/2 | 0/3 |
| Elevated INRGeneral disorders | 0/10 | 0/4 | 1/9 | 0/24 | 0/2 | 0/2 | 0/2 | 1/3 |
| ThrombocytopeniaGeneral disorders | 2/10 | 1/4 | 2/9 | 6/24 | 0/2 | 0/2 | 0/2 | 0/3 |
| Decreased phosphorusGeneral disorders | 0/10 | 1/4 | 0/9 | 0/24 | 0/2 | 0/2 | 0/2 | 0/3 |
| Elevated creatinineGeneral disorders | 2/10 | 1/4 | 1/9 | 0/24 | 0/2 | 0/2 | 0/2 | 0/3 |
10 patients were enrolled in the Phase I trial. One patient was withdrawn leaving nine patients for analysis. 49 patients were enrolled in the Phase II trial. Two patients were withdrawn leaving 47 patients who completed the study and were included in the analysis.
| Age, Customized(years) | Phase II - 1.2 g/kg Smoflipid | Phase II - 1.4 g/kg Smoflipid | Phase II - 1.6 g/kg Smoflipid | Phase II - Control | Phase I - 1.0 g/kg Smoflipid | Phase I - 1.2 g/kg Smoflipid | Phase I - 1.4 g/kg Smoflipid | Phase I - 1.6 g/kg Smoflipid | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, y | 71 (59 to 76) | 63 (61 to 67) | 67 (48 to 77) | 68 (60 to 73) | 66 (65 to 67) | 53 (42 to 64) | 53 (44 to 63) | 59 (58 to 62) | 65 (57 to 74) |
| Sex: Female, Male(Participants) | Phase II - 1.2 g/kg Smoflipid | Phase II - 1.4 g/kg Smoflipid | Phase II - 1.6 g/kg Smoflipid | Phase II - Control | Phase I - 1.0 g/kg Smoflipid | Phase I - 1.2 g/kg Smoflipid | Phase I - 1.4 g/kg Smoflipid | Phase I - 1.6 g/kg Smoflipid | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 8 | 0 | 2 | 10 | 1 | 0 | 1 | 2 | 24 |
| Male | 2 | 4 | 7 | 14 | 1 | 2 | 1 | 1 | 32 |
| Race (NIH/OMB)(Participants) | Phase II - 1.2 g/kg Smoflipid | Phase II - 1.4 g/kg Smoflipid | Phase II - 1.6 g/kg Smoflipid | Phase II - Control | Phase I - 1.0 g/kg Smoflipid | Phase I - 1.2 g/kg Smoflipid | Phase I - 1.4 g/kg Smoflipid | Phase I - 1.6 g/kg Smoflipid | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 2 | 5 | 11 | 1 | 1 | 0 | 1 | 26 |
| White | 5 | 1 | 4 | 12 | 1 | 1 | 2 | 2 | 28 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Region of Enrollment(participants) | Phase II - 1.2 g/kg Smoflipid | Phase II - 1.4 g/kg Smoflipid | Phase II - 1.6 g/kg Smoflipid | Phase II - Control | Phase I - 1.0 g/kg Smoflipid | Phase I - 1.2 g/kg Smoflipid | Phase I - 1.4 g/kg Smoflipid | Phase I - 1.6 g/kg Smoflipid | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 10 | 4 | 9 | 24 | 2 | 2 | 2 | 3 | 56 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2018 to primary completion in Apr 2023, 56 months.
Results were first posted in Aug 2025, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SMOFlipid